132 related articles for article (PubMed ID: 7176660)
1. Biotransformation rate (in vitro) and systemic potency (in vivo) of the topical glucocorticoid budesonide in male and female rats.
Andersson P; Brattsand R; Edsbäcker S; Källström L; Ryrfeldt A
J Steroid Biochem; 1982 Dec; 17(6):703-6. PubMed ID: 7176660
[TBL] [Abstract][Full Text] [Related]
2. In vitro biotransformation of glucocorticoids in liver and skin homogenate fraction from man, rat and hairless mouse.
Andersson P; Edsbäcker S; Ryrfeldt A; von Bahr C
J Steroid Biochem; 1982 Jun; 16(6):787-95. PubMed ID: 7109582
[TBL] [Abstract][Full Text] [Related]
3. Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids.
Brattsand R; Thalén A; Roempke K; Källström L; Gruvstad E
J Steroid Biochem; 1982 Jun; 16(6):779-86. PubMed ID: 7109581
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17 alpha,21-dipropionate in human liver and lung homogenate.
Andersson P; Ryrfeldt A
J Pharm Pharmacol; 1984 Nov; 36(11):763-5. PubMed ID: 6150981
[TBL] [Abstract][Full Text] [Related]
5. Metabolic acetal splitting of budesonide. A novel inactivation pathway for topical glucocorticoids.
Edsbäcker S; Andersson P; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1987; 15(3):412-7. PubMed ID: 2886320
[TBL] [Abstract][Full Text] [Related]
6. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man.
Johansson SA; Andersson KE; Brattsand R; Gruvstad E; Hedner P
Eur J Clin Pharmacol; 1982; 22(6):523-9. PubMed ID: 7128664
[TBL] [Abstract][Full Text] [Related]
7. Effect of structural alterations on the biotransformation rate of glucocorticosteroids in rat and human liver.
Andersson P; Lihné M; Thalén A; Ryrfeldt A
Xenobiotica; 1987 Jan; 17(1):35-44. PubMed ID: 3825176
[TBL] [Abstract][Full Text] [Related]
8. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects.
Edsbäcker S; Andersson P; Lindberg C; Paulson J; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1987; 15(3):403-11. PubMed ID: 2886319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.
Ryrfeldt A; Andersson P; Edsbäcker S; Tönnesson M; Davies D; Pauwels R
Eur J Respir Dis Suppl; 1982; 122():86-95. PubMed ID: 6958498
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity.
Thalén A; Brattsand R
Arzneimittelforschung; 1979; 29(11):1687-90. PubMed ID: 543875
[TBL] [Abstract][Full Text] [Related]
11. Metabolic pathways of the topical glucocorticoid budesonide in man.
Edsbäcker S; Jönsson S; Lindberg C; Ryrfeldt A; Thalén A
Drug Metab Dispos; 1983; 11(6):590-6. PubMed ID: 6140145
[TBL] [Abstract][Full Text] [Related]
12. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects.
Thalén A; Brattsand R; Andersson PH
Acta Derm Venereol Suppl (Stockh); 1989; 151():11-9; discussion 47-52. PubMed ID: 2624062
[TBL] [Abstract][Full Text] [Related]
13. Effect of three weeks' treatment with budesonide on in vitro contractile and relaxant airway effects in the rat.
Gustafsson B; Persson CG
Thorax; 1989 Jan; 44(1):24-7. PubMed ID: 2928986
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of the epimeric glucocorticoid budesonide.
Ryrfeldt A; Edsbäcker S; Pauwels R
Clin Pharmacol Ther; 1984 Apr; 35(4):525-30. PubMed ID: 6705451
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.
Stoeck M; Riedel R; Hochhaus G; Häfner D; Masso JM; Schmidt B; Hatzelmann A; Marx D; Bundschuh DS
J Pharmacol Exp Ther; 2004 Apr; 309(1):249-58. PubMed ID: 14718604
[TBL] [Abstract][Full Text] [Related]
16. Allergen-induced mucosal exudation of plasma into rat ileum and its inhibition by budesonide.
Gustafsson B; Persson CG
Scand J Gastroenterol; 1992 Jul; 27(7):587-93. PubMed ID: 1641585
[TBL] [Abstract][Full Text] [Related]
17. Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat.
Fabia R; Ar'Rajab A; Willén R; Brattsand R; Erlansson M; Svensjö E
Aliment Pharmacol Ther; 1994 Aug; 8(4):433-41. PubMed ID: 7986968
[TBL] [Abstract][Full Text] [Related]
18. Topical anti-inflammatory activity of the glucocorticoid budesonide on airway mucosa. Evidence for a "hit and run" type of activity.
Miller-Larsson A; Brattsand R
Agents Actions; 1990 Jan; 29(1-2):127-9. PubMed ID: 2327315
[No Abstract] [Full Text] [Related]
19. Prospects for future topical glucocorticoid development.
Brattsand R; Särnstrand B
Acta Derm Venereol Suppl (Stockh); 1989; 151():37-46; discussion 47-52. PubMed ID: 2624065
[TBL] [Abstract][Full Text] [Related]
20. Biotransformation in vitro of the 22R and 22S epimers of budesonide by human liver, bronchus, colonic mucosa and skin.
Cortijo J; Urbieta E; Bort R; Castell JV; Ruiz-Bravo C; Martinez J; Palacios-Pelaez R; Lledó S; Morcillo EJ
Fundam Clin Pharmacol; 2001 Feb; 15(1):47-54. PubMed ID: 11468013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
